Quantcast

Latest Genentech Stories

2014-03-25 12:29:41

Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014 /PRNewswire/ -- Decision Resources Group finds that efficacy more than any other factors drives oncologists' prescribing of targeted therapies for breast cancer and, according to the majority of surveyed oncologists, the escalating overall cost of drug treatment for breast cancer has little or no impact...

2014-03-25 00:23:20

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" [http://www.researchandmarkets.com/research/llq9cw/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to...

2014-03-24 20:22:55

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation Report on China Trastuzumab Market, 2009-2018" [http://www.researchandmarkets.com/research/czqbv2/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main...

2014-03-24 12:30:49

LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analysis of the US Retinal Therapeutics Market Improvements in Administration and Efficacy Drive GrowthSince the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research...

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...

2014-03-18 12:31:29

The Majority of Surveyed Oncologists Have Already Prescribed Kadcyla, Just Nine Months Post-Launch, According to Findings from Decision Resources Group BURLINGTON, Mass., March 18, 2014 /PRNewswire/ -- Decision Resources Group finds that, at 18-months post-launch, over 85 percent of surveyed oncologists have prescribed Roche/Genentech's Perjeta for metastatic HER2-positive breast cancer. Since the last wave of the report was fielded six months previously, the average number of Perjeta-treated...

2014-03-13 16:28:25

NEW YORK, March 13, 2014 /PRNewswire/ -- Weight Watchers International, Inc. (NYSE: WTW) today announced the unanimous election of Cynthia Elkins as a member of the Company's Board of Directors effective as of March 30, 2014, the beginning of the Company's second quarter of fiscal 2014. Ms. Elkins will also serve on the Audit Committee of the Company's Board of Directors. "I am very pleased to welcome Cindy to our Board of Directors," commented Raymond Debbane, the Company's Chairman...

2014-03-12 12:29:13

Surveyed U.S. Payers Look for Substantial Delivery Achievements for Inclusion of New Agents in Formularies, According to Findings from Decision Resources Group BURLINGTON, Mass., March 12, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European retinal specialists ascribe a moderate to high unmet need for wet age-related macular degeneration (AMD) therapies that improve visual acuity. In line with this finding, surveyed U.S. retinal specialists expect that they...

2014-03-11 16:26:30

INCLINE VILLAGE, Nev., March 11, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase. The forecasted growth in revenues is driven by increased fourth quarter 2013 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®), and...

2014-03-03 16:25:50

- Annual Revenues Increased 18 Percent during 2013 - INCLINE VILLAGE, Nev., March 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2013. http://photos.prnewswire.com/prnvar/20110822/SF55808LOGO Total revenues in 2013 increased 18 percent to $442.9 million from $374.5 million in 2012. For the fourth quarter of 2013, total revenues were $110.1 million, compared to $86.0 million in...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related